Luc Verhees has been appointed Chief Clinical Officer in Approxima to lead global clinical affairs and support the clinical development of the Approxima percutaneous right ventricular reshaping technology to treat patients with tricuspid valve regurgitation.

Milan, Italy, September 9, 2026 – **Approxima Srl** announced today the **appointment** of **Luc Verhees**, as **Chief Clinical Officer (CCO)**.

Luc joins the Approxima leadership team to strengthen the Company's clinical development capabilities and support the translation of its technology into the clinical development phase. As Chief Clinical Officer, he will lead global clinical affairs, clinical operations and therapy development.

Luc brings more than 30 years of experience in cardiovascular clinical research, with senior positions at leading global medtech companies including LivaNova (Sorin), Medtronic, Boston Scientific and private venture-backed companies including CoreValve, Xeltis and HighLife. Earlier this year both Highlife and Xeltis have obtained CE mark on their respective devices with Luc playing a key role in their clinical development.

"I am very excited to join the Approxima team, which has developed what could be a groundbreaking technology that will literally open a new door to the treatment of right heart diseases, including right ventricular dilation and tricuspid regurgitation. This innovation is designed to serve a broad patient population, unlike other transcatheter therapies, due to its minimal anatomical exclusion criteria (i.e. annulus size). Throughout my career, I have been dedicated to advancing new technologies and leadership within the cardiovascular field. This is the first time since the introduction of bare-metal stents that I have seen a truly transformative innovation that does not rely on the conventional vascular access route. I believe it has enormous potential to improve the lives of a large number of patients who currently have limited treatment options." stated Luc Verhees.

"On behalf of the entire team, I am pleased to welcome Luc to Approxima. His expertise will significantly strengthen our ability to build a robust clinical program, execute our clinical strategy and generate the evidence required to bring the Approxima technology to patients." commented Michal Jaworek, CEO and Co-founder of Approxima.

"Advancing from preclinical to clinical development will mark an important stage for Approxima. Luc brings the experience we need to navigate this phase successfully. I am very much looking forward to working with him." added Dr. Paolo Denti, CMO of Approxima.

About Approxima

Approxima was founded in 2020. Approxima aspires to provide a transformative therapeutic solution for patients with tricuspid valve regurgitation based on the approach of ventricular reshaping which can restore physiological functioning of the tricuspid valve. The device is intended to be implanted into the heart of a patient via a percutaneous and straightforward beating-heart procedure.
The Headquarter office of Approxima is located in Milan, Italy.

https://www.approximamedical.com/